Xeriant Inc (XERI) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 4, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q3 FY2026, filed May 15, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the XERI SEC filings page.
This page shows Xeriant Inc (XERI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Balance-sheet contraction dominates Xeriant’s profile: liabilities expanded while assets and equity deteriorated, leaving operations dependent on outside financing.
Assets shrank from$1.1M in FY2021 to$68K in FY2025, while liabilities rose. That combination moved equity from$922K positive to-$5.8M , revealing a financing structure increasingly disconnected from operating scale.
In FY2024, the cash-conversion gap was narrower than the accounting loss: net loss was
The current-ratio collapse from 3.3x in FY2021 to 0.3x in FY2022 indicates short-term obligations overtook current assets early, before the later asset contraction. By FY2025, reported long-term debt was only
Financial Health Signals
Xeriant Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The metrics below are current.
Key Financial Metrics
Earnings & Revenue
Not reported for Q3 2026.
Not reported for Q3 2026.
Not reported for Q3 2026.
Cash & Balance Sheet
Xeriant Inc held $25K in cash against $0 in long-term debt as of Q3 2026.
Not reported for Q3 2026.
Not reported for Q3 2026.
Margins & Returns
None of these metrics is reported for Q3 2026.
Capital Allocation
Xeriant Inc invested $30K in research and development in Q3 2026. This represents a decrease of 1.9% from the same quarter a year earlier. Against the prior quarter it is up 81.8%.
Not reported for Q3 2026.
Not reported for Q3 2026.
XERI Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $30K-1.9% | $16K+108586.7% | $54K+103.2% | N/A | $30K-55.2% | $15-100.0% | $27K-1.6% | N/A |
| SG&A Expenses | $59K-42.5% | $28K-80.5% | $25K-55.9% | N/A | $102K+49.4% | $146K+99.9% | $56K+7.7% | N/A |
| Operating Income | N/A | -$231K+31.1% | -$304K+15.3% | N/A | N/A | -$336K+1.3% | -$359K-12.5% | N/A |
| EBITDA | N/A | -$231K+31.2% | -$304K+15.3% | N/A | N/A | -$335K+1.3% | -$358K-12.5% | N/A |
| Interest Expense | $46K-31.1% | $36K-30.3% | $45K-27.3% | N/A | $66K+131.6% | $51K | $62K+198.0% | N/A |
| Income Tax | -$24K | -$16K | $125K | N/A | $0 | $0 | $0 | N/A |
| Net Income | N/A | -$298K+28.7% | N/A | N/A | N/A | -$417K | -$372K-8.8% | N/A |
| EPS (Basic) | $0.00 | $0.00 | $0.00 | N/A | $0.00 | $0.00 | $0.00 | N/A |
| EPS (Diluted) | $0.00 | $0.00 | $0.00 | $0.00+100.0% | $0.00 | $0.00 | $0.00 | -$0.01 |
| Diluted Shares (Avg) | 882M+34.7% | 780M+30.8% | 2.37B+332.3% | N/A | 655M+45.7% | 596M+40.8% | 548M | N/A |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit.
XERI Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $44K-40.2% | $103K-62.6% | $72K-79.8% | $68K-90.4% | $73K-83.8% | $277K+114.4% | $355K+38.3% | $713K+326.6% |
| Current Assets | $34K-45.4% | $95K-64.7% | $62K-80.7% | $57K-91.5% | $62K-84.1% | $269K+402.8% | $320K+90.2% | $664K+904.0% |
| Cash & Equivalents | $25K-54.2% | $77K-69.9% | $52K-82.6% | $45K-93.1% | $54K-85.7% | $254K+552.1% | $300K+1122.0% | $653K+959.8% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $3.0M-48.8% | $2.9M-53.0% | $2.9M-51.6% | $5.9M-8.9% | $5.8M-32.8% | $6.1M-23.6% | $6.0M-16.3% | $6.5M+63.3% |
| Non-Current Liabilities | -$2.9M-0.1% | -$2.9M | -$2.9M | -$2.9M-0.5% | -$2.9M | N/A | N/A | -$2.9M-2.5% |
| Long-Term Debt | $0 | $508 | $2K | $3K | N/A | N/A | N/A | N/A |
| Total Equity | -$2.9M+48.9% | -$2.8M+52.5% | -$2.8M+49.8% | -$5.8M-1.2% | -$5.7M+30.0% | -$5.8M+25.9% | -$5.6M+18.4% | -$5.8M-51.7% |
| Retained Earnings | -$26.8M+4.2% | -$26.4M+3.9% | -$26.1M+3.6% | -$28.3M-6.1% | -$28.0M-9.6% | -$27.5M-9.2% | -$27.1M-12.9% | -$26.7M-13.0% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Current Liabilities.
XERI Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | N/A | -$206K+48.3% | -$178K+49.7% | -$172K+53.6% | -$366K+12.0% | -$398K-18.3% | -$353K-14.6% | -$370K-170.1% |
| Depreciation & Amortization | $465+23.0% | $465+23.0% | $465+23.0% | $465+23.0% | $3780.0% | $3780.0% | $3780.0% | $3780.0% |
| Stock-Based Compensation | $162K+224.0% | $35K+141.3% | $60K-72.6% | N/A | $50K | $15K | $218K | N/A |
| Capital Expenditures | N/A | N/A | N/A | $2K | N/A | N/A | N/A | $0 |
| Free Cash Flow | N/A | N/A | N/A | -$174K+53.1% | N/A | N/A | N/A | -$370K-170.1% |
| Investing Cash Flow | -$3K | $0 | $0 | -$2K | $0 | $0+100.0% | $0-100.0% | $0+100.0% |
| Financing Cash Flow | $175K+6.1% | $230K-34.7% | $185K | $165K-74.6% | $165K-78.0% | $352K | $0+100.0% | $650K+15.1% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
XERI Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Current Ratio, Debt-to-Equity, Asset Turnover, FCF Margin.
Note: Shareholder equity is negative (-$5.8M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Xeriant Inc XERI | FY2025 | N/A | N/A | N/A | $11.4M | — |
| Helio Corp HLEO | FY2025 | $3.9M | -$4.0M | N/A | $8.2M | — |
| Tel Instrument Electronics TIKK | FY2025 | $9.3M | -$4.9M | -52.7% | $8.3M | — |
Where Xeriant Inc Ranks
Frequently Asked Questions
How much debt does Xeriant Inc have?
As of fiscal year 2025, Xeriant Inc (XERI) had $45K in cash and equivalents against $3K in long-term debt.
What are Xeriant Inc's total assets?
Xeriant Inc (XERI) had $68K in total assets as of fiscal year 2025, including both current and long-term assets.
What are Xeriant Inc's capital expenditures?
Xeriant Inc (XERI) invested $2K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Xeriant Inc spend on research and development?
Xeriant Inc (XERI) invested $69K in research and development during fiscal year 2025.
What is Xeriant Inc's P/E ratio?
Xeriant Inc (XERI) has no price-to-earnings ratio at the moment: no net income reported. The market capitalization is $11.4M as of Sep 4, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Xeriant Inc's price-to-sales ratio?
Xeriant Inc (XERI) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $11.4M as of Sep 4, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Why is Xeriant Inc's debt-to-equity ratio negative or not reported?
Xeriant Inc (XERI) has negative shareholder equity of -$5.8M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.